FDA fast track designation supports development of pelareorep plus bevacizumab/FOLFIRI in 2L KRAS-mutant MSS mCRC, enabling more frequent regulatory engagement and potential accelerated pathways.
The interplay between host immunity, the microbiota, and cancer is a rapidly evolving area of immuno-oncology. An increasing body of evidence highlights the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results